key: cord-0868112-db5bj75d
authors: Singh, Rahul; Bhardwaj, Vijay Kumar; Das, Pralay; Bhattacherjee, Dhananjay; Zyryanov, Grigory V.; Purohit, Rituraj
title: Benchmarking the ability of novel compounds to inhibit SARS-CoV-2 main protease using steered molecular dynamics simulations
date: 2022-04-29
journal: Comput Biol Med
DOI: 10.1016/j.compbiomed.2022.105572
sha: 9f42ab8cebbf6d0892a2662816e4d2d0acf21868
doc_id: 868112
cord_uid: db5bj75d

BACKGROUND: The SARS-CoV-2 main protease (M(pro)) is an attractive target in the COVID-19 drug development process. It catalyzes the polyprotein's translation from viral RNA and specifies a particular cleavage site. Due to the absence of identical cleavage specificity in human cell proteases, targeting M(pro) with chemical compounds can obstruct the replication of the virus. METHODS: To explore the potential binding mechanisms of 1,2,3-triazole scaffolds in comparison to co-crystallized inhibitors 11a and 11b towards M(pro), we herein utilized molecular dynamics and enhanced sampling simulation studies. RESULTS AND CONCLUSION: All the 1,2,3-triazole scaffolds interacted with catalytic residues Cys145 and His41 of the M(pro) and binding pocket residues involving Met165, Glu166, Ser144, Gln189, His163, and Met49. Furthermore, the adequate binding free energy and potential mean force of the topmost compound 3h was comparable to the experimental inhibitors 11a and 11b of M(pro). Overall, the current analysis could be beneficial in developing the SARS-CoV-2 M(pro) potential inhibitors.

Coronaviruses (CoVs) are considered as an alarming threat to humans. The 2019-nCoV is extremely homologous with SARS-CoV [1] . CoVs are viruses that carry a single positive-stranded enveloped RNA and induce a broad array of neurological, respiratory, and gastrointestinal disorders in the host [2, 3] . However, SARS-CoV-2 is more transmissible than the other two coronaviruses. They are the parts of the Coronavirinae subfamily in the Nidovirales order of Coronaviridae group. From the findings of recent researches, this virus has a compact genomic arrangement, including various nonstructural and structural proteins, such as proteases, spike glycoprotein, and nucleocapsid [4] . The

CoVs Main protease (M pro ) is one of the vastly investigated targets to develop probable inhibitors [5] .

The M pro is also recognized as 3-Chymotrypsin-like protease (3CL pro ) [6, 7] . The M pro is liable to process the polyproteins produced by the viral RNA transcription. The M pro separates the polyproteins by its proteolytic action to create polypeptides (non-structural) [8] . These polypeptides are needed to generate four necessary structural proteins (Membrane, Spike-RBD, nucleocapsid, and Envelope) and other subordinate proteins [9, 10] . The inhibition of M pro would fundamentally block the expansion of the virus in the human body [6, 8] .

The M pro is present in the form of a dimer (A and B protomers) in active biological conditions. Every protomer includes three domains. The domains I and II (8-101 and 102-184 residues) carry a catalytic dyad made by His41 and Cys145 residues. These parts contains 6 anti-parallel β-barrel stranded structures. Domain III (201-303) comprises 5 α-helices building a globular cluster (antiparallel) [8] . The domain III controls the arrangement of the physiologically dynamic two monomeric conformation by furnishing salt bridge interchanges linking Arg4 and Glu290 of each protomer. The aperture of domains I and II resembles a substrate-binding site. The binding site comprises four (S1, S1', S2, and S4) subsites formed by nearby residues [11] . The nonexistence of homologs of M pro in J o u r n a l P r e -p r o o f humans fits it to be an appropriate target without cytotoxicity [6, 12] . Several possibilities for COVID-19 therapy were considered from the starting of the pandemic. These include monoclonal antibodies, oligonucleotide-based treatments, peptides, interferon therapies, vaccines, drug re-purposing, and small molecules. To date, only Remdesivir is authorized for emergency use. The lack of specific FDAapproved medicines against M pro of SARS-CoV-2 still exists. Several in-silico investigations have proposed prospective inhibitors from diverse source against distinct proteins of SARS-CoV-2 [5, [13] [14] [15] [16] [17] . In earlier studies, the 1,2,3-triazole scaffolds were identified to possess antiviral, antiinflammatory, antibacterial, and anti-cancerous properties [18] [19] [20] [21] . In addition, the 1,2,3-triazole scaffolds were also shown to have an antiviral effect on the M pro in experimental studies [22] [23] [24] .

Based on the above-information, we aimed to identify the M pro inhibitors with high-affinity binding and stability from our selected molecules in comparison to co-crystallized inhibitors by employing molecular dynamics (MD) and enhanced sampling simulations.

The 3D co-crystal structure of the M pro (PDB ID: 6M0K) with 1.50 Å resolution was obtained in PDB format with co-crystallized molecules 11a and 11b (IC 50 : 0.053 ± 0.005 and 0.040 ± 0.002 μM) [25] .

The earlier synthesized seven novel molecules (3f, 3g, 3h, 3i, 3j, 5d, and 5e) out of eighteen 1,2,3triazole scaffolds were chosen for the study ( Figure S1 ) [26] . The structure of protein was prepared by the "prepare protein" tool of the Discovery studio [27] . Gaussian16 DFT (energy minimization) protocols were used to optimize the ligand geometry [28] .

J o u r n a l P r e -p r o o f

The molecular docking was done using the (CDOCKER method) BIOVIA Discovery Studio (DS) 2018 [29] . We assigned the binding pocket of co-crystallized molecule 11b for the docking of 1,2,3-triazole scaffolds. After selecting 11b, the SBD-site sphere showed the attributes X:-11.622; Y:11.881; Z:68.704 with a 12.00 Å radius for sphere object covering the binding site. The 6M0K was assigned as input receptor in parameter values setup and a set of chosen molecules defined as input ligands. The orientations to refine, random conformations, parallel processing, and simulated annealing parameters were specified as default. After completing calculations, the top hit complexes were selected on the basis of CDOCKER interaction energy and visualized the protein-ligand interactions. All the complexes were then prepared for MD simulations to examine the stability of the protein-ligand complexes.

We selected docked 1,2,3-triazole scaffolds-M pro complexes along with 11a and 11b (standard M pro inhibitors) for 100 ns MD simulation applying GROMOS96 43a1 force field to validate the docking outcomes and estimate their stability [30] [31] [32] . The topology files for ligands were acquired from the PRODRG2 server [33] . We selected the simple-point charge water model to solvate the systems [34] .

We created a 954.61 nm3 volume cubic box for all the designated systems. After running the gmx genion command, 4 Na+ ions were added, and the energy minimization was accomplished by employing 50,000 steps of the steepest descent. The simulations were executed following the periodic boundary conditions with NVT accompanied by an NPT ensemble. Berendsen's coupling algorithm was carried throughout the restraint MD runs to keep the 300K temperature and 1bar pressure steady, respectively [35, 36] The electrostatic associations were specified by the PME algorithm, with a 1.2 nm coulomb cutoff [37] . The LINCS algorithm was designated to constraint the bond lengths [38] .

The molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) approach was utilized to evaluate all the compound's binding free energies with M pro to determine complexes stability [39] . The g_mmpbsa package was employed to assess the binding free energies of 1,2,3-triazole scaffolds and experimental inhibitor complexes. Evaluation of binding free energy implicates enumeration of nonpolar solvation, Van der Waals, solvent-accessible surface area, electrostatic, and polar energies.

Schlitter proposes the Quasiharmonic (QH) technique to estimate the relative and absolute entropies.

These entropies were calculated on the basis of the assessment of the covariance matrix of Cartesian coordinates by MD simulation. Schlitter's approach directs only a determinant's computation, which was the premise for its endorsement in computational biology. In Schlitter's framework, the absolute entropy calculation describes the upper limit of the quantum mechanics entropy [40] .

The time-dependent external pulling force is applied in steered MD simulation to separate the compound from the protein's binding site [41] . The steered MD simulations were performed using the GROMACS software v4.6.7 [42] . The energy of all the identified protein-ligand structures was minimized before starting the pulling process. We applied the external pulling force on the z-axis along the simulated pathway to discharge the compound from the protein's binding site. The simulation for 500 ns was executed at the 0.01 nm/ps pull rate and allocated a 500 kJ/mol/nm 2 spring constant. We constructed the force profiles of each system, determining the steered MD trajectories. Moreover, we assembled the distance summary to produce umbrella sampling slots [43] . Slot spacing of 0.1 nm is used to initiate the center of mass (COM) distance of 3 nm. After that, we generated sampling windows at each spacing distance of 0.2 nm. A 10 ns simulation run was allotted for every sampling window, finishing in 1170 ns of simulation period for each chosen protein-ligand complexes. Then the J o u r n a l P r e -p r o o f trajectories were constrained to the WHAM computation procedure to construct potential mean force (PMF) graphs. The PMF graph is utilized to compute the binding free energies.

Molecular docking is a method of structure-based drug design to determine the necessary residue involved in protein-ligand interactions, as well as the binding affinity [13, 44] . The 11a, 11b (cocrystallized), and 1,2,3-triazole scaffolds received after ligand preparation were docked at the binding pocket of M pro . We estimated the CDOCKER interaction energy of all the docked compounds, as represented in Table 1 . It has to be stated that a greater (more negative) interaction energy score signifies more favorable binding of protein-ligand [45] . 

As the protein-ligand interactions are static entities, MD simulations are deemed to be a crucial part of any in-silico analysis [46] [47] [48] . It provides detailed data concerning to the protein-ligand interactions with a dynamic aspect [49, 50] . MD simulation was implemented to obtain more profound insights into the impact of protein flexibility and structural alteration in the interaction profile of the complexes. The system is stabilized and equilibrated if it acquire lower RMSD with constant variations for the complete simulation [51] . RMSD was measured for C-α atoms of protein backbone for all eight complexes. The RMSD graphs of M pro complexed with 11a, 11b, 3f, 3g, 3h, 3i, 3j, 5d, and 5e were displayed in Figure 2 . We saw that the maximum and minimum RMSDs achieved by all the M pro complexes were very low, ranging from 0.2 nm to 0.45 nm. In contrast, the average RMSD for apoprotein was ~0.34 nm ( Figure S3 ). Such low RMSD values strongly indicated conformational stability that the protein had obtained in the presence of compounds. The graph represented stable trajectories with steady and lesser fluctuations, signifying that the protein backbone experienced minor structural disturbances.

The RMSF, measure of flexibility of Cα atoms of a protein is a crucial parameter in determining stability of protein-ligand complexes. The residues play an indispensable role in attaining a stable conformation for a stable protein-ligand complexes [52] . RMSF for all the M pro complexes were measured and displayed on a graph, shown in figure S4 . The fluctuations of several binding site residues Glu166, Cys145, Asn142, Phe140, Met165, Met49, His41, and Leu141 were minor in all the M pro complexes. Small fluctuations of these binding site residues recommended a high stability of the J o u r n a l P r e -p r o o f M pro binding pocket. Additionally, the data intimated that the residues involved in the binding were also liable for the stable RMSD of the M pro complexes.

Furthermore, the radius of gyration (Rg) is applied to determine the compactness of the proteinligand complexes [53] . The Rg can estimate the unfolding and folding of protein upon ligand binding.

The high Rg value bestows unfolded (less compactness) protein-ligand complex. The average Rg values of M pro complexes with selected compounds were between 2.09 and 2.13 nm, while between 2.13 and 2.10 nm for co-crystallized compounds (Figure 3) . As a result, every complex presented an approximately similar expression of compactness and uniform numbers of Rg compared to the cocrystallized compounds. This implied that the selected compounds helped to sustain the complex's stability and compactness, similar to co-crystallized compounds.

Additionally, we also executed ensemble cluster analysis to elucidate the protein's considerable flexibility towards the compounds and the degree of stability as a complex [54] . We conducted an ensemble cluster investigation over the MD trajectories of all the M pro complexes, as shown in figure 4 .

This interpretation furnished a substantial number of clusters (ranging from 46 to 57) for M pro complexes with all the selected compounds. Their average RMSD value ranging from 0.169 to 0.191 nm and energy of matrix between 3.00 and 3.75 nm were admitted for the complex's conformational stability. The less number of members in a cluster indicated that the mean conformation of the complexes in three-dimensional space is compact, with substantially less variance between clusters, referring that the protein-ligand complexes were conformationally stable.

The energy of interaction indicates the strength of the protein-ligand complex. Therefore, to validate the interaction energy of molecular docking analysis, a thorough investigation was conducted to estimate the binding free energy using the MM-PBSA (Table 2) approach. The data indicated that the selected compounds showed comparable binding free energies with M pro as shown by co-crystallized J o u r n a l P r e -p r o o f compounds ( Figure S5 ). These results inferred that all the selected compounds made a strong complex with the M pro . The Van der Waal, SASA, and electrostatic energy furnished favorable energy to the total binding free energy for all the protein-ligand complexes. In contrast, the polar solvation energy demonstrated an unfavorable contribution to total binding free energy. Therefore, these MM-PBSA results recommended that the predicted energies of all the selected compounds were thermodynamically favorable. In addition, we have also explored the per residue contribution energy to analyze the residues responsible for the difference in binding free energy of the 11a, 11b, and 3h (Table   S1 ). Furthermore, the configurational entropy was calculated for the chosen protein-ligand complexes with molecules 11a, 11b, and 3h (topmost) by a QH approach. The entropic effects are vital in molecular association, protein folding, stability, and ligand binding [55] . The entropy due to the QH calculation unveiled that all the selected protein-ligand complexes had comparable entropic values (Table S2 ). These outcomes showed that the complex with 3h molecule acquired similar entropy and 

Umbrella sampling simulation is a prominent technique for computing the potential mean force (PMF) to examine protein-ligand binding/unbinding procedures [56, 57] . The reaction coordinate (ξ) along the free-energy profile was examined using the "gmx wham." The received PMF value of every studied system is illustrated as a reaction coordinates (ξ) function. We calculated the potential mean force required for the unbinding of the topmost molecule obtained from MM-PBSA analysis compared to cocrystallized inhibitors 11a and 11b of M pro . The plotted binding free energy can be outlined as the variation between the highest and least PMF curves, as represented in Figure 6 . The co-crystallized inhibitors 11a and 11b exhibited binding free energy values of -64.70 ± 2.15 kJ/mol and -79.97 ± 1.11 kJ/mol, respectively, while the 3h delivered convenient binding free energy (-78.91 ± 2.26 kJ/mol) value. The free energy initiates, fall to the lowest value, and eventually extends to a stable value when ξ acquires 3.0-3.5 nm ( Figure 6 ). This span resembles the condition where the protein and ligand interaction is lost, and the ligand detached from the binding cavity of M pro along the unbinding pathway. These free energy profiles complement our MM-PBSA calculation, where binding free energy of 3h was comparable to the co-crystallized molecules 11a and 11b. In the end, the selected 3h compound could be considered as lead to develop the M pro inhibitors.

The urgency to prevent COVID-19 has suggested discovering potential lead molecules that can be utilized to target the SARS-CoV-2 M pro . This research has implemented molecular docking, MD simulation, MM-PBSA, enhanced sampling methods toward M pro to recognize the prospective compounds with higher affinity and stability compared to co-crystallized compounds. MD simulation studies validated the docking outcomes and suggested that the selected compounds have the ability to bind and block the SARS-CoV-2 M pro similarly as co-crystallized compounds. In addition, the umbrella sampling analysis also reported that the force required for 3h to leave the binding site of the M pro was J o u r n a l P r e -p r o o f 

The 2019 novel coronavirus resource

Coronaviruses-drug discovery and therapeutic options

SARS and MERS: Recent insights into emerging coronaviruses

Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors

Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery

The newly emerged SARS-Like coronavirus HCoV-EMC also has an "Achilles'' heel": Current effective inhibitor targeting a 3C-like protease

Design of wide-spectrum inhibitors targeting coronavirus main proteases

Coronavirus main proteinase (3CLpro) Structure: Basis for design of anti-SARS drugs, Science (80-. )

Identification of novel and selective agonists for ABA receptor PYL3

A computational approach for rational discovery of inhibitors for non-structural protein 1 of SARS-CoV-2

Bioactive molecules of Tea as potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2

In-silico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors

Targeting COVID-19 (SARS-CoV-2) main protease through active phytocompounds of ayurvedic medicinal plants -Emblica officinalis (Amla), Phyllanthus niruri Linn. (Bhumi Amla) and Tinospora cordifolia (Giloy) -A molecular docking and simulation study

Novel 1,2,3-Triazole Derivatives as Potential Inhibitors against Covid-19 Main Protease: Synthesis, Characterization, Molecular Docking and DFT Studies

Synthesis and antiviral evaluation of 4′-(1,2,3-triazol-1-yl) thymidines

Recent Trends in 1,2,3-Triazolo-Nucleosides as Promising Anti-Infective and Anticancer Agents

Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Cu salts-free mechanochemical approach towards multifunctionalized 1,2,3-triazoles and anti-seizure drug Rufinamide analogs

Dassault Systemes BIOVIA, Discovery Studio Modelling Environment

Efficient Geometry Minimization and Transition Structure Optimization Using Interpolated Potential Energy Surfaces and Iteratively Updated Hessians

CHARMM: A program for macromolecular energy, minimization, and dynamics calculations

Algorithms for highly efficient, load-balanced, and scalable molecular simulation

GROMACS: Fast, flexible, and free

PRODRG: A tool for high-throughput crystallography of protein-ligand complexes

The missing term in effective pair potentials

Molecular dynamics with coupling to an external bath

Polymorphic transitions in single crystals: A new molecular dynamics method

Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems

LINCS: A Linear Constraint Solver for molecular simulations

G-mmpbsa -A GROMACS tool for high-throughput MM-PBSA calculations

Estimation of absolute and relative entropies of macromolecules using the covariance matrix

Steered Molecular Dynamics

Steered Molecular Dynamics Simulation in Rational Drug Design

G-whams-a free Weighted Histogram Analysis implementation including robust error and autocorrelation estimates

Identification of selective cyclindependent kinase 2 inhibitor from the library of pyrrolone-fused benzosuberene compounds: an in silico exploration

Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs

What Contributes to Serotonin-Norepinephrine Reuptake Inhibitors' Dual-Targeting Mechanism? the Key Role of Transmembrane Domain 6 in Human Serotonin and Norepinephrine Transporters Revealed by Molecular Dynamics Simulation

How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics

Exploring the Binding Mechanism of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators in Clinical Trials by Molecular Dynamics Simulations

Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder

De novo design of novel protease inhibitor candidates in the treatment of SARS-CoV-2 using deep learning, docking, and molecular dynamic simulations

Methods of protein structure comparison

Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COVID-19 drugs: Designing, docking and molecular dynamics simulation study

Size-independent comparison of protein three-dimensional structures

Peptide folding: When simulation meets experiment

Estimation of conformational entropy in protein-ligand interactions: A computational perspective

Effective estimation of ligand-binding affinity using biased sampling method

Molecular Mechanism for the Allosteric Inhibition of the Human Serotonin Transporter by Antidepressant Escitalopram

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ✔ J o u r n a l P r e -p r o o f